Trials / Not Yet Recruiting
Not Yet RecruitingNCT01003028
Reduction of Remifentanil-related Complications
Reduction of Remifentanil-related Complications by Limiting Maximum Plasma Concentration During Target-controlled Infusion
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is intended to evaluate the effect of decreasing the maximum plasma concentration target of remifentanil of the Target Controlled Infusion system on the the incidence of major and minor side-effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remifentanil (Limited) - Target Controlled Infusion system | Limit max plasma concentration to 9.8 ng/ml |
| DRUG | Remifentanil (Control) - Target Controlled Infusion system | Use 20 ng/ml as max plasma concentration |
Timeline
- Start date
- 2024-11-01
- Primary completion
- 2025-12-01
- Completion
- 2026-12-01
- First posted
- 2009-10-28
- Last updated
- 2023-12-01
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01003028. Inclusion in this directory is not an endorsement.